TABLE 1.
Patient characteristics at baseline
| Characteristic | Value |
|---|---|
| No. of ENF-treated patients | 88 |
| No. of male patients (%) | 57 (64.8) |
| Median age (yr [IQR]) | 43 (38.5-48.5) |
| No. (%) of risk factors | |
| Sexual behavior | 36 (40.9) |
| Drug addiction | 20 (22.7) |
| Unknown | 31 |
| No. (%) of patients at CDC stage C | 42 (47.7) |
| Median viremia at baseline (log HIV RNA | |
| copies/ml [IQR]) | 5.0 (4.9-5.1) |
| Median CD4 cell count at baseline (cells/μl [IQR]) | 87 (36-149) |
| Median time since diagnosis (yr [IRQ]) | 12 (8.5-16.3) |
| Median no. of ENF-coadministered drugs (IQR) | 3 (2-3) |
| Median no. of resistance mutations (IQR)a | |
| NRTI | 5 (4-6) |
| Non-NRTI | 1 (1-2) |
| PI | 8 (6-12) |
a
The drug resistance mutations considered in this study were those listed by the International AIDS Society.